Objectives: To investigate whether lesion imaging features may condition the outcome of CT-guided lung biopsy (CTLB) and to develop a scoring system of biopsy outcome prediction. Methods: This is a single center retrospective study on 319 CTLBs that were performed in 319 patients (167 males/152 females, mean age 68 ± 12.2). Uni- and multivariate analysis were performed aiming to assess the imaging features that are likely to be correlated to a negative biopsy outcome and patients were stratified in groups accordingly. Results: Technical success was 100%. 78% of the biopsies (250/319) led to a concrete histology report (218 malignant/32 benign). The remaining lesions led to concrete histology at a second attempt that occurred on a later time. Multivariate analysis revealed increased risk of inconclusive result for nodules with low fludeoxyglucose uptake [odds ration (OR) = 2.64, 95% confidence interval (CI) 1.4–4.97; p = 0.003], for nodules with diameter smaller than 18 mm (OR = 2.03, 95% CI 1.14–3.62; p = 0.017) and for nodules that are located in one of the lung bases (OR = 1.96, 95% CI 1.06–3.62; p = 0.033). Three different groups of patients were identified accordingly with low (50%) probability of obtaining an inconclusive biopsy sample. Conclusion: This study confirms that percutaneous CT-guided biopsy in nodules that are either small in diameter or present low positron emission tomography-fludeoxyglucose uptake or are in one of the lung bases may lead to inconclusive histology. This information should be factored when planning percutaneous biopsies of such nodules in terms of patient informed consent and biopsy strategy. Advances in knowledge: Inconclusive histology after lung biopsy may be subject to factors irrelevant to technical success. Lung biopsy histology outcomes may be predicted and avoided after adequate planning.

(1) Introduction and Aim: The aim of this study is to investigate the prognostic value, in terms of response and survival, of CT-based radiomics features for patients with HCC undergoing drug-eluting beads transarterial chemoembolization (DEB-TACE). (2) Materials and Methods: Pre-treatment CT examinations of 50 patients with HCC, treated with DEB-TACE were manually segmented to obtain the tumor volumetric region of interest, extracting radiomics features with TexRAD. Response to therapy evaluation was performed basing on post-procedural CT examination compared to pre-procedural CT, using modified RECIST criteria for HCC. The prognostic value of texture analysis was evaluated, investigating the correlation between radiomics features, response to therapy and overall survival. Three models based on texture and clinical variables and a combination of them were finally built; (3) Results: Entropy, skewness, MPP and kurtosis showed a significant correlation with complete response (CR) to TACE (all p < 0.001). A predictive model to identify patients with a high and low probability of CR was evaluated with an ROC curve, with an AUC of 0.733 (p < 0.001). The three models built for survival prediction yielded an HR of 2.19 (95% CI: 2.03–2.35) using texture features, of 1.7 (95% CI: 1.54–1.9) using clinical data and of 4.61 (95% CI: 4.24–5.01) combining both radiomics and clinical data (all p < 0.0001). (4) Conclusion: Texture analysis based on pre-treatment CT examination is associated with response to therapy and survival in patients with HCC undergoing DEB-TACE, especially if combined with clinical data.

Objective: Endovascular repair of visceral artery aneurysms (VAAs) and visceral artery pseudoaneurysms (VAPAs) using covered stent grafts is a novel technique that preserves efferent vessel patency and prevents end-organ ischemia; however, long-term results are lacking in the literature. This study aims to evaluate ultra-long-term outcomes (>5 years) using CT angiography (CTA) and technical aspects of covered stents in treating VAAs and VAPAs. Methods: A single-center retrospective study was conducted on patients with VAAs and VAPAs treated with stent grafts between 2004 and 2023. The study included an ultra-long-term follow-up using CTA. Stent graft patency, aneurysm characteristics, technical success, 30-day and long-term follow-up clinical success, and mortality were assessed. Results: Among 23 patients presenting with VAAs and VAPAs treated exclusively with covered stents implantation, 7 (mean age: 68 years, SD 14), including 5 with VAAs and 2 with VAPAs, met the inclusion criteria for the study. Six of the seven patients underwent elective procedures with no significant periprocedural complications. Both technical and 30-day clinical success rates were 100%. The mean follow-up period was 10 years (125 months SD 53). At the 5-year follow-up, 71% of stent grafts remained patent. No patient experienced aneurysm sac revascularization or rupture. Stent obstruction did not affect survival. Conclusions: This study demonstrates that endovascular covered stenting is a durable and effective treatment for VAAs and VAPAs, even in the ultra-long term, with a patency rate of 71% at a mean CTA follow-up of 125 months, the longest reported to date and no cases of sac revascularization. Stent thrombosis was significantly associated with VAPAs.